AbbVie (NYSE:ABBV) and Calibr today announced an expanded strategic collaboration to advance several innovative preclinical and... AbbVie (NYSE:ABBV) today announced the British Journal of ...

Immunogen (IMGN) to Resume Trading at 8 a.m. Following News of Takeover by AbbVie (ABBV) Earlier: AbbVie Inc (NYSE:ABBV).

Defensive stocks, bonds, and gold are essential in an all-weather portfolio to navigate the Trump era's economic ...

A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient ...

Enigma Biomedical USA, Inc. (EB USA) today announced that it has selected two (2) four-repeat tau (4R Tau) protein PET imaging biomarkers to advance into Phase 1 (Ph1) studies. Previously, EB USA ...

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

AbbVie is currently addressing serious health ... 30% from Western Europe, Canada, Japan and Australia and 40% from the fastest-growing economies, including India, China, Russia and Brazil.

AbbVie has secured its fourth FDA approval for ... and the UK), plus Japan and Canada, although it noted competition is growing in the category. Vraylar will have to contend with low-cost generic ...

The first Korean company granted Breakthrough Therapy Designation (BTD) from the U.S. FDA-Clinical trials and results from a three-year follow-up show significant improvements compared to existing ...

The current US Commerce Secretary - Howard Luttnick - has once again targeted Ireland, calling our country his 'favourite tax ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Existing research indicates that the accuracy of a Parkinson’s disease diagnosis hovers between 55% and 78% in the first five years of assessment. That’s partly because Parkinson’s sibling movement ...